ArticleCancer research2020
HACE1 Prevents Lung Carcinogenesis via Inhibition of RAC-Family GTPases.
Open access · bronzeAbstract read
In one paragraph
Article in Cancer research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
1.6field-weighted citation impact, top 14% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 34 citations in OpenAlex.
- Adipocyte-derived exosomal miR-27a-3p promotes macrophage M1 polarization via HACE1/RAC1/STAT3 axis to exacerbate the progression of childhood asthma.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- HECT ubiquitin ligases as regulators of inflammatory signalling.Cell death and differentiation · 2026Review
- Article
- Article
- HACE1 as a bridge between oxidative stress and autophagy.Frontiers in immunology · 2025Review
- LINC00161 upregulated by M2-like tumor-associated macrophages promotes hepatocellular carcinoma progression by methylating HACE1 promoters.Cytotechnology · 2024Article
- NEDD4L Suppresses Proliferation and Promotes Apoptosis by Ubiquitinating RAC2 Expression and Acts as a Prognostic Biomarker in Clear Cell Renal Cell Carcinoma.International journal of molecular sciences · 2024Article
- Advances of E3 ligases in lung cancer.Biochemistry and biophysics reports · 2024Review
- Unveiling the role of HACE1 in cervical cancer: implications for human papillomavirus infection and prognosis.Translational cancer research · 2024Article
- Structural mechanisms of autoinhibition and substrate recognition by the ubiquitin ligase HACE1.Nature structural & molecular biology · 2024Article
- NET1 is a critical regulator of spindle assembly and actin dynamics in mouse oocytes.Reproductive biology and endocrinology : RB&E · 2024Article
- Inhibition of esophageal cancer progression through HACE1-TRIP12 interaction and associated RAC1 ubiquitination and degradation.Journal of Cancer · 2024Article
- Article
- Article
- Optineurin links Hace1-dependent Rac ubiquitylation to integrin-mediated mechanotransduction to control bacterial invasion and cell division.Nature communications · 2022Article
- Macrophage ALDH2 (Aldehyde Dehydrogenase 2) Stabilizing Rac2 Is Required for Efferocytosis Internalization and Reduction of Atherosclerosis Development.Arteriosclerosis, thrombosis, and vascular biology · 2022Article
- A novel tumor doubling time-related immune gene signature for prognosis prediction in hepatocellular carcinoma.Cancer cell international · 2021Article
- Review
- Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 6 institutions in 7 countries.
Melanie Kogler *Institute of Molecular Biotechnology of the Austrian Academy of Sciences, Vienna BioCentre, Vienna, Austria.ORCID 0000-0001-8107-2441
Luigi Tortola *Institute of Molecular Biotechnology of the Austrian Academy of Sciences, Vienna BioCentre, Vienna, Austria. josef.penninger@ubc.ca luigi.tortola@biol.ethz.ch.
Gian Luca NegriDepartment of Pathology and Laboratory Medicine, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.ORCID 0000-0001-7722-8888
Alexandra LeopoldiInstitute of Molecular Biotechnology of the Austrian Academy of Sciences, Vienna BioCentre, Vienna, Austria.
Amal M El-NaggarDepartment of Pathology and Laboratory Medicine, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.ORCID 0000-0002-3202-6171
Stefan MereiterInstitute of Molecular Biotechnology of the Austrian Academy of Sciences, Vienna BioCentre, Vienna, Austria.
Carlos Gomez-DiazInstitute of Molecular Biotechnology of the Austrian Academy of Sciences, Vienna BioCentre, Vienna, Austria.ORCID 0000-0002-6416-806X
Roberto NitschInstitute of Molecular Biotechnology of the Austrian Academy of Sciences, Vienna BioCentre, Vienna, Austria.
Davide TortoraDepartment of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada.ORCID 0000-0001-5007-3206
Anoop M KavirayaniVienna BioCentre Core Facilities, Vienna BioCentre, Vienna, Austria.ORCID 0000-0003-3874-3101
Bianca V GappInstitute of Molecular Biotechnology of the Austrian Academy of Sciences, Vienna BioCentre, Vienna, Austria.
Shuan RaoInstitute of Molecular Biotechnology of the Austrian Academy of Sciences, Vienna BioCentre, Vienna, Austria.ORCID 0000-0003-1501-7860
Iris UribesalgoInstitute of Molecular Biotechnology of the Austrian Academy of Sciences, Vienna BioCentre, Vienna, Austria.
David HoffmannInstitute of Molecular Biotechnology of the Austrian Academy of Sciences, Vienna BioCentre, Vienna, Austria.
Domagoj CikesInstitute of Molecular Biotechnology of the Austrian Academy of Sciences, Vienna BioCentre, Vienna, Austria.
Maria NovatchkovaResearch Institute of Molecular Pathology, Vienna BioCentre, Vienna, Austria.
David A WilliamsDivision of Hematology/Oncology, Boston Children's Hospital, Boston, Massachusetts.
Jeffrey M TrentTranslational Genomics Research Institute (TGen), Phoenix, Arizona.ORCID 0000-0003-0183-4202
Fumiyo IkedaInstitute of Molecular Biotechnology of the Austrian Academy of Sciences, Vienna BioCentre, Vienna, Austria.ORCID 0000-0003-0407-2768
Mads DaugaardDepartment of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
Astrid HagelkruysInstitute of Molecular Biotechnology of the Austrian Academy of Sciences, Vienna BioCentre, Vienna, Austria.ORCID 0000-0003-3015-4038
Poul H SorensenDepartment of Pathology and Laboratory Medicine, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
Josef M PenningerInstitute of Molecular Biotechnology of the Austrian Academy of Sciences, Vienna BioCentre, Vienna, Austria. josef.penninger@ubc.ca luigi.tortola@biol.ethz.ch.
Institute of Molecular Biotechnology · ATUniversity of British Columbia · CABoston Children's Hospital · USResearch Institute of Molecular Pathology · ATTranslational Genomics Research Institute · USVienna Biocenter · AT
Funding
Austrian Science Fund FWF Z 271CIHR 377771CIHR FDN-143280European Research Council 233407Swiss National Science Foundation 145993
Abstract
HACE1 is an E3 ubiquitin ligase with important roles in tumor biology and tissue homeostasis. Loss or mutation of
Indexed as
Gene Expression Regulation, NeoplasticAnimalsApoptosisBiomarkers, TumorCarcinogenesisCell ProliferationHumansLung NeoplasmsMiceMice, Inbred C57BLMice, KnockoutPrognosisrac1 GTP-Binding ProteinRAC2 GTP-Binding Proteinrac GTP-Binding ProteinsTumor Cells, CulturedBiomarkers, TumorHACE1 protein, mouserac1 GTP-Binding ProteinRAC2 GTP-Binding Proteinrac GTP-Binding ProteinsTumor Suppressor ProteinsUbiquitin-Protein Ligases
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.